Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

18,852 total articles

Odysight.ai Signs Commercial Collaboration Agreement with GACI Technologies to Expand AI-Powered Predictive Maintenance into the French Aerospace and Defense Market

Odysight.ai Signs Commercial Collaboration Agreement with GACI Technologies to Expand AI-Powered Predictive Maintenance into the French Aerospace and Defense Market

Odysight.ai Inc., a U.S.-listed company specializing in AI/ML visual sensing for predictive and condition-based maintenance, has entered into a commercial collaboration agreement with French aerospace and defense firm GACI Technologies. The partnership aims to bring Odysight.ai's AI-driven predictive maintenance systems to France's advanced aerospa…

Kandal M Venture Limited Issues Guidance Projecting Improved Top and Bottom Line for Full Year Fiscal 2026

Kandal M Venture Limited Issues Guidance Projecting Improved Top and Bottom Line for Full Year Fiscal 2026

Kandal M Venture Limited, a Nasdaq-listed contract manufacturer of affordable luxury leather goods, projects improved revenue and net income for fiscal 2026 versus fiscal 2025. The company is diversifying its customer base to markets with lower tariff impact such as the UK, Japan, and other countries, and expanded manufacturing to the Philippines t…

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

Cogent Biosciences announced updated preclinical results for its CGT1263 pan-KRAS inhibitor and CGT4255 ErbB2 inhibitor at the AACR Annual Meeting 2026. The data suggest improved selectivity and reduced toxicity for CGT1263, and enhanced brain penetration plus synergistic effects with HER2 ADC therapies for CGT4255. These advancements underscore th…

WEBUY GLOBAL LTD. Launches Exclusive Antarctica Expedition Cruise Under Premium Brand Altitude Travel, Achieves Over US$777,500 in First Month Total Transaction Value

WEBUY GLOBAL LTD. Launches Exclusive Antarctica Expedition Cruise Under Premium Brand Altitude Travel, Achieves Over US$777,500 in First Month Total Transaction Value

WEBUY GLOBAL LTD. announced the launch of a premium Antarctica expedition cruise under its high-end Altitude Travel brand, generating over US$777,500 in total transaction value in its first month. The exclusive chartered 15-day cruise offers immersive expedition experiences and AI-assisted personalization to attract affluent travelers, signaling st…

Myseum.AI Accepted into Advanced Micro Devices AI Developer Program

Myseum.AI Accepted into Advanced Micro Devices AI Developer Program

Myseum.AI, a privacy-first social media and AI technology company, announced its acceptance into the Advanced Micro Devices (AMD) AI Developer Program, gaining access to AMD's tools and resources to accelerate AI development. Concurrently, CEO Darin Myman was highlighted as a 'Next Super Stock' by Wall Street Reporter, reflecting investor interest …

KUSTOM ENTERTAINMENT AND CYCURION ANNOUNCE AGREEMENT ON TERMS FOR SALE OF LEGACY VIDEO SOLUTIONS SEGMENT

KUSTOM ENTERTAINMENT AND CYCURION ANNOUNCE AGREEMENT ON TERMS FOR SALE OF LEGACY VIDEO SOLUTIONS SEGMENT

Kustom Entertainment and Cycurion have reached a revised agreement for the sale of Kustom's legacy video solutions segment for $5.5 million, including cash, a secured note, performance incentives, and stock warrants. The deal supports Kustom's focus on core growth areas, while enabling Cycurion to expand its cybersecurity and AI portfolio. The tran…

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Upstream Bio announced upcoming presentations at the 2026 American Thoracic Society International Conference showcasing new Phase 2 data on Verekitug, their novel TSLP receptor antagonist, in treating chronic rhinosinusitis with nasal polyps and comorbid asthma. The data highlights clinical effects and biomarker impacts, underscoring its potential …

VEON to Release 1Q26 Earnings Update on May 13, 2026

VEON to Release 1Q26 Earnings Update on May 13, 2026

VEON Ltd., a Nasdaq-listed global digital operator, will release its financial and operating results for Q1 2026 on May 13, 2026. The company will host a conference call and livestream to provide insights, with enhanced shareholder engagement through a Q&A platform beginning May 6, 2026.

HII Introduces Distributed Maritime Operations Framework in Support of U.S. Navy’s “Hedge Strategy”

HII Introduces Distributed Maritime Operations Framework in Support of U.S. Navy’s “Hedge Strategy”

HII announced at the 2026 Sea-Air-Space Expo a new distributed maritime operations framework integrating manned and autonomous systems, open architecture technologies, and modular payloads to support the U.S. Navy's Hedge Strategy. The approach promotes interoperability across maritime, air, space, cyber, and land domains using HII's Minotaur Missi…

Fortuna Renews Share Buyback Program

Fortuna Renews Share Buyback Program

Fortuna Mining Corp. announced the renewal of its normal course issuer bid (NCIB) authorizing the repurchase of up to 15.2 million common shares, representing 5% of outstanding shares, starting May 4, 2026. The company will repurchase shares on the NYSE and cancel them, aiming to enhance shareholder value by buying back shares trading below their i…

Kyivstar to Release 1Q26 Earnings Update on May 13, 2026

Kyivstar to Release 1Q26 Earnings Update on May 13, 2026

Kyivstar Group Ltd., the first Ukrainian company listed on Nasdaq, announced it will release its first quarter 2026 earnings and operational results on May 13, 2026. The company also announced a follow-up conference call on May 14 to discuss these results with senior management. Kyivstar is a leading digital operator in Ukraine providing mobile, fi…

Dime to Release Earnings on April 23, 2026

Dime to Release Earnings on April 23, 2026

Dime Community Bancshares, a New York State-chartered trust company with $15 billion in assets and leading deposit market share on Greater Long Island, will release its Q1 2026 earnings on April 23 before U.S. markets open. The CEO will discuss financial results on a conference call with Q&A, accessible via webcast and telephone. A replay will be a…

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Kura Oncology reported encouraging preliminary data from a subset analysis of its ongoing FIT-001 clinical trial combining darlifarnib with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC) previously treated with cabozantinib. The combination demonstrated a 44% objective response rate and 94% disease control rate, with tumor sh…

Immuron Double Digit 3Q Sales Growth

Immuron Double Digit 3Q Sales Growth

Immuron Limited announced unaudited Q3 sales growth of 16% globally for Travelan®, an over-the-counter immunotherapy product targeting gastrointestinal pathogens. Growth was driven by increased brand awareness and marketing in Australia, steady advancements in U.S. sales despite currency headwinds, and significant gains in Canadian retail penetrati…

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

MiNK Therapeutics announced Phase II trial results showing their cell therapy agenT-797, combined with botensilimab and balstilimab, achieved a 77% disease control rate and durable survival beyond 20 months in patients with advanced PD-1 refractory gastroesophageal cancer. An induction treatment strategy yielded significant improvements in progress…

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Zymeworks Inc. disclosed multiple new preclinical and clinical data sets at the AACR 2026 meeting, highlighting its advanced antibody-drug conjugate (ADC) programs targeting difficult-to-treat cancers, including RAS-mutated tumors. Key presentations showcased efficacy, tumor-selective delivery, and favorable tolerability of novel ADCs such as ZW191…